Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population

BMJ Open Diabetes Research and Care

Volumn 3, Issue 1, 2015, Pages

  Kim, Jungmee ^a   Lee, Joongyub ^b   Shin, Cheol Min ^c   Lee, Dong Ho ^c   Park, Byung Joo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CORTICOSTEROID; DEXIBUPROFEN; KETOROLAC; LOXOPROFEN; MISOPROSTOL; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; REBAMIPIDE; SEROTONIN UPTAKE INHIBITOR; SUCRALFATE; TALNIFLUMATE; WARFARIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; ICD-10; INFORMATION PROCESSING; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; VERY ELDERLY;

EID: 85021038005     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2015-000133     Document Type: Article

References (39)

1. Bhala N, Emberson J, Merhi A, et al, Coxib traditional Nsaid Trialists' Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79.
2. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.
3. American Diabetes A. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1):S14-80.
4. Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38.
5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
6. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012;307:2286-94.
7. Sirois C, Moisan J, Poirier P, et al. Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. Ann Med 2014;46:335-40.
8. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20.
9. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6.
10. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26:734-53.
11. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-22.
12. Garbe E, Kloss S, Suling M, et al. High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. Eur J Clin Pharmacol 2013;69:549-57.
13. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
15. Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-44.
16. Wu CY, Wu MS, Kuo KN, et al. Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut 2011;60:1038-42.
17. Fiaccadori E, Maggiore U, Clima B, et al. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int 2001;59:1510-19.
18. Fujita T, Kutsumi H, Sanuki T, et al. Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug-or low-dose aspirin-induced gastrointestinal injuries. J Gastroenterol 2013;48:559-73.
19. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173-9.
20. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300-6.
21. Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220-30.
22. Linden MD, Tran HA. Overcoming aspirin treatment failure in diabetes. Crit Rev Clin Lab Sci 2012;49:183-98.
23. Chittaranjan A, Chethan KB, Sandarsh S. Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure. Int Clin Psychopharmacol 2013;28:145-55.
24. Kimmel SE, Schelleman H, Berlin JA, et al. The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol 2011;72:514-17.
25. Freedland KE, Carney RM. Depression as a risk factor for adverse outcomes in coronary heart disease. BMC Med 2013;11:131.
26. Kikuchi Y, Iwase M, Fujii H, et al. Association of severe hypoglycemia with depressive symptoms in patients with type 2 diabetes: the Fukuoka Diabetes Registry. BMJ Open Diabetes Res Care 2015;3:e000063.
27. Shin D, Oh YH, Eom CS, et al. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol 2014;261:686-95.
28. Scuteri A, Modestino A, Fedullo F, et al. Depression treatment selectively modifies arterial stiffness in older participants. J Gerontol A Biol Sci Med Sci 2013;68:719-25.
29. Kemp AH, Brunoni AR, Santos IS, et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am J Psychiatry 2014;171:1328-34.
30. Castellsague J, Pisa F, Rosolen V, et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013;22:365-75.
31. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012;35:1127-46.
32. Lee SH, Han CD, Yang IH, et al. Prescription pattern of NSAIDs and the prevalence of NSAID-induced gastrointestinal risk factors of orthopaedic patients in clinical practice in Korea. J Korean Med Sci 2011;26:561-7.
33. Shau WY, Chen HC, Chen ST, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord 2012;12:4.
34. Chang CH, Shau WY, Kuo CW, et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010;41:1884-90.
35. Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004;27:411-20.
36. Spies CM, Stemmler E, Buttgereit F. How to mechanistically explain the CONDOR study data. Med Hypotheses 2015;84:14-19.
37. Gryglewski RJ, Dembinska-Kiec A, Korbut R. A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation. Acta Biol Med Ger 1978;37:715-23.
38. Schneeweiss S, Glynn RJ, Tsai EH, et al. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 2005;16:17-24.
39. Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013;144:1384-93, 93 e1-2; quiz e18-9.